Mode
Text Size
Log in / Sign up

Beta-thalassemia

0 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Beta-thalassemia

7 trials tracked for Beta-thalassemia: 3 in phase 3 or 4 and 3 with published results. The most-cited published study has 268 citations.

7Trials tracked
3Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 3 3 Phase 2 3 Other / NA 1
  1. Phase 3 A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia, Who do Not Have a β0/β0 Genotype Completed · 268 cited
  2. Phase 3 An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Transfusions Due to Beta (β) Thalassemia Completed · 117 cited
  3. Phase 3 A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Participants With Transfusion-Dependent β-Thalassemia Completed · 40 cited
  4. Phase 2 Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Preliminary Efficacy of VIT-2763 in β-thalassaemia Completed
  5. Phase 2 Cardiac T2* in Beta-thalassemia Patients on Deferasirox Treatment Completed
  6. Phase 2 Safety and Pharmacodynamic Study of an Oral Iron Chelator Given for 6 Months to Patients With Iron Overload Completed
Show 1 more trials
  1. N/A Evaluation of Low-cost Techniques for Detecting Sickle Cell Disease and β-thalassemia in Nepal and Canada Completed

Showing the 7 most-cited and recently-updated of 7 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
No published articles yet for this condition. Check back soon.